JACQUE LANGFORD-KARRE: Open Payments
NPI 1174003941 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,309 in 252 payments from 19 companies in 2025. Trend: 2023 $182 · 2024 $3,112 · 2025 $4,309
Food & beverage: $4,199Education: $109
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 70 | $1,144 |
| ABBVIE INC. | 35 | $570 |
| Madrigal Pharmaceuticals | 28 | $549 |
| Gilead Sciences, Inc. | 28 | $434 |
| GENZYME CORPORATION | 10 | $316 |
| Ardelyx, Inc. | 17 | $300 |
| Lilly USA, LLC | 8 | $241 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $225 |
| Phathom Pharmaceuticals, Inc. | 21 | $164 |
| Regeneron Healthcare Solutions, Inc. | 4 | $95 |
Products named: TREMFYA, REZDIFFRA, DUPIXENT, IBSRELA, RINVOQ, OMVOH, VOQUEZNA, ENTYVIO.
Industry payments across NE — which companies pay providers there.
